主角治疗

最新新闻

• 评级变动
  H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• Form 144 | Protagonist Therapeutics(PTGX.US) Officer Proposes to Sell 8.26 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $173
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $167
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178
  \u5e02\u573a\u8d44\u8baf · 2026/8/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。